It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

REALMS

REALMS is a retrospective study based on the analysis of medical records in order to collect real-world evidence for the efficacy and safety of fingolimod in RRMS patients (N=275) from Portuguese MS centers during the 3-year follow-up

Adverse events by year after initiating fingolimod treatment1

REALMS table-v2
aThree opportunistic infections, one hepatic enzymes>3×ULN and one disease activity could not be assigned to a specific year given the dates are lacking
Link to article DoI
border
Abbreviations
AE, adverse event; MS, multiple sclerosis; RRMS, relapsing-remitting MS; ULN, upper limit of normal
Reference
1. Batista S et al. Neurol Sci. 2020 Sep 30. doi: 10.1007/s10072-020-04726-6.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.